NCT05995444 - A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

July 26, 2023

Study Completion Date

August 3, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

Epetraborole and matching placebo

Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)

DRUG

Epetraborole

Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)

DRUG

Placebo

Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)

DRUG

Moxifloxacin

Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)

Trial Locations (1)

423001, Tempe